Results 81 to 90 of about 282,663 (297)
Leukemia is a cancer of the blood and bone marrow; there are many types of leukemia, depending on which type of white blood cell is involved. Treatment varies with the type and stage of disease.
A. Heidari, R. Gobato
semanticscholar +1 more source
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives
ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as ...
Giuseppe G. Loscocco, Paola Guglielmelli
wiley +1 more source
Újdonságok, aktualitások a polycythaemia vera diagnosztikájában és kezelésében | Diagnosis and treatment of polycythaemia vera: state of the art [PDF]
Absztrakt A polycythaemia vera a Philadelphia-negatív krónikus myeloid neoplasiák közé tartozó ritka neoplasia, amelyre az emelkedett vörösvérsejttömeg okozta hiperviszkozitás a jellemző.
Borbényi, Zita+2 more
core +1 more source
Oral Idasanutlin in Patients with Polycythemia Vera.
A limited number of drugs are available to treat patients with polycythemia vera (PV) and essential thrombocythemia (ET). We attempted to identify alternative agents that may target abnormalities within malignant hematopoietic stem and progenitor cells ...
J. Mascarenhas+12 more
semanticscholar +1 more source
ABSTRACT Allogeneic hematopoietic stem‐cell transplantation (HCT) remains the only potentially curative therapy for patients with myelodysplastic neoplasms (MDS) and myelofibrosis (MF) and is the standard care for eligible patients with higher‐risk disease. Despite significant advancements, both diseases pose unique challenges due to their clinical and
Nico Gagelmann, Nicolaus Kröger
wiley +1 more source
Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]
The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core +2 more sources
Topics of Interest in Women With Myeloproliferative Neoplasms
Women with MPN: life‐cycle phases, specific risks, and influencing factors. ABSTRACT Overview Sex and gender have emerged as central modifiers of disease biology, phenotype, and clinical outcomes in myeloproliferative neoplasms (MPNs). This review will uniquely highlight issues affecting women with MPN and articulate their relevant determinants ...
Natasha Szuber+2 more
wiley +1 more source
ABSTRACT The latest updates to the classification of hematolymphoid malignancies using the World Health Organization (WHO, 5th ed.) and ICC (International Consensus Classification) criteria highlight the critical need for comprehensive and precise cytogenomic data for diagnosis, prognostication, and treatment.
Rashmi Kanagal‐Shamanna+18 more
wiley +1 more source
We tested the hypothesis that levels of pentraxin high sensitivity C-reactive protein and pentraxin 3 might be correlated with cardiovascular complications in patients with essential thrombocythemia and polycythemia vera.
Tiziano Barbui+15 more
doaj +1 more source
Pipobroman therapy of polycythemia vera [PDF]
Abstract Between 1971 and 1981, 74 patients with polycythemia vera were treated with pipobroman using a high-dose induction, low-dose maintenance regimen. Complete remission was achieved in 51 of 54 previously untreated patients (94.4%) and in 17 of 20 patients (85%) previously treated wih radioactive phosphorus (32 p) and busulfan.
Duhamel G+4 more
openaire +4 more sources